key: cord-1001349-pxvb88ki authors: Correa-Rodríguez, María; Callejas-Rubio, José-Luis; Rueda-Medina, Blanca; Ríos-Fernández, Raquel; de la Hera -Fernández, Javier; Centeno, Ortego title: Clinical course of Covid-19 in a cohort of patients with Behçet disease date: 2021-12-28 journal: Med Clin (Barc) DOI: 10.1016/j.medcli.2021.11.009 sha: 112256077af26536102ec79e2137636cf6a081b0 doc_id: 1001349 cord_uid: pxvb88ki Objective: The implications of Covid-19 in patients with Behçet´s disease (BD) are unknown. Patients with BD usually take long-term therapy with therapeutic agents that have been tested in Covid-19 patients. We aimed to assess the prevalence of Covid-19 in a cohort of patients with BD and investigate whether those patients with a long-term treatment with colchicine, tumor necrosis factor inhibitors (TNFi) or glucocorticoids are at reduced or increased prevalence of Covid-19 related clinical outcomes. Methods: A retrospective study was conducted among 244 patients with BD (86.1% females; mean age 43.95±11.11 years). Each participant completed an online questionnaire regarding demographics, medical conditions, dispensed colchicine, TNFi or oral glucocorticoids, Covid-19 infection, clinical symptoms and recovery. Results: The prevalence of Covid-19 infection was 14.75%. Regarding dose of colchicine, the presence of ageusia was lower in patients taking 0.5 mg/day of colchicine compared to those taking 1.5 mg/day (p=0.021). The prevalence of dyspnoea was significantly higher in patients taking TNFi compared with those without therapy (p=0.032). With regards to oral glucocorticoids, no significant differences were found. Conclusions: The prevalence of Covid-19 among patients with BD seems tobe higher than that among the general population in Spain. Continuous TNFi therapy might increase the prevalence of worse clinical outcomes such as dyspnea; oral glucocorticoids and colchicine apparently provided no protection against the Covid-19 related clinical outcomes of patients with BD. Objetivo: Se desconocen las implicaciones de la Covid-19 en pacientes con enfermedad de Behçet (EB). Los pacientes con EB generalmente tienen tratamiento de larga duración con agentes terapéuticos que se han probado en pacientes con Covid-19. Nuestro objetivo fue evaluar la prevalencia de Covid-19 en una cohorte de pacientes con EB e investigar si aquellos pacientes con un tratamiento de larga duración con colchicina, inhibidores del factor de necrosis tumoral (TNFi) o glucocorticoides tienen una prevalencia reducida o aumentada en los resultados clínicos de la Covid-19. Métodos: Se realizó un estudio retrospectivo en 244 pacientes con EB (86,1% mujeres; edad media 43,95±11,11años). Cada participante completó un cuestionario en línea sobre datos demográficos, afecciones médicas, tratamiento con colchicina, TNFi o glucocorticoides orales, infección por Covid-19, síntomas clínicos y recuperación. Resultados: La prevalencia de la infección por Covid-19 fue del 14,75%. En cuanto a la dosis de colchicina, la presencia de ageusia fue menor en los pacientes que tomaban 0,5 mg/día de colchicina en comparación con los que tomaban 1,5 mg/día (p=0,021). La prevalencia de disnea fue significativamente mayor en los pacientes que tomaban TNFi en comparación con aquellos sin terapia (p = 0.032). Con respecto a los glucocorticoides orales, no se encontraron diferencias significativas. Conclusiones: La prevalencia de Covid-19 en pacientes con EB parece ser superior a la de la población general en España. La terapia continua con TNFi podría aumentar la prevalencia de peores resultados clínicos como la disnea; los glucocorticoides orales y la colchicina aparentemente no proporcionan protección contra los resultados clínicos relacionados con la Covid-19 en pacientes con BD. Objetivo Se desconocen las implicaciones de la Covid-19 en pacientes con enfermedad de Behçet (EB). Los pacientes con EB generalmente tienen tratamiento de larga duración con agentes terapéuticos que se han probado en pacientes con Covid-19. Nuestro objetivo fue evaluar la prevalencia de Covid-19 en una cohorte de pacientes con EB e investigar si aquellos pacientes con un tratamiento de larga duración con colchicina, inhibidores del factor de necrosis tumoral (TNFi) o glucocorticoides tienen una prevalencia reducida o aumentada en los resultados clínicos de la Covid-19. Se realizó un estudio retrospectivo en 244 pacientes con EB (86,1% mujeres; edad media 43,95±11,11años). Cada participante completó un cuestionario en línea sobre datos demográficos, afecciones médicas, tratamiento con colchicina, TNFi o glucocorticoides orales, infección por Covid-19, síntomas clínicos y recuperación. La prevalencia de la infección por Covid-19 fue del 14,75%. En cuanto a la dosis de colchicina, la presencia de ageusia fue menor en los pacientes que tomaban 0,5 mg/día de colchicina en comparación con los que tomaban 1,5 mg/día (p=0,021). La prevalencia de disnea fue significativamente mayor en los pacientes que tomaban TNFi en comparación con aquellos sin terapia (p = 0.032). Con respecto a los glucocorticoides orales, no se encontraron diferencias significativas. La prevalencia de Covid-19 en pacientes con EB parece ser superior a la de la población general en España. La terapia continua con TNFi podría aumentar la prevalencia de peores Page 4 of 21 J o u r n a l P r e -p r o o f 4 resultados clínicos como la disnea; los glucocorticoides orales y la colchicina aparentemente no proporcionan protección contra los resultados clínicos relacionados con la Covid-19 en pacientes con BD. Palabras clave: enfermedad de Behçet; COVID-19; colchicina; inhibidor del factor de necrosis tumoral alfa; glucocorticoides. Coronavirus disease 2019 (Covid-19) is a global pandemic caused by the respiratory droplet transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is responsible for many deaths worldwide. Severe disease induces an exaggerated inflammatory response known as the "cytokine storm". Behçet´s disease (BD) is a chronic multisystemic inflammatory disorder characterized by recurrent skin mucosa lesions and uveitis 1 . The pathogenesis is unclear but it has been established that immunological aberrations might play a main role in the BD development 2 . To date, there is limited evidence regarding the susceptibility and severity of Covid-19 infection is patients displaying BD 3, 4 and only case series studies have explored the characteristics and outcomes of BD patients with Covid-2019 5,6 . Since the clinical manifestations of BD are heterogeneous, the treatment has to be individualized and depends on organ damage, severity of the disease, and patient's characteristics. Immunosuppressive therapy along with colchicine have been recommended for mucocutaneous and joint involvement 7 . Evidence suggests that tumor necrosis factor inhibitors (TNFi) are important agents in the treatment of patients with severe and resistant BD. Thus, patients with BD usually take long-term therapy with colchicine, TNFi and glucocorticoids, that have been tested in Covid-19 patients with conflicting results. The potential preventive effect of continuous treatment with colchicine, an anti-inflammatory and immunomodulator that has been used as chronic treatments in certain rheumatological diseases, on Covid-19 related outcomes remains poorly characterized [8] [9] [10] . Previous studies stated that colchicine treatment helped prevent a "cytokine storm" phenomenon and reduced Covid-19 complications [11] [12] [13] [14] [15] [16] [17] [18] whereas others reported that colchicine may not be beneficial in patients with Covid-19 since its effects of increasing cytosolic pH and preventing cytokine storms are very weak 19 . The use of glucocorticoids in the treatment of Covid-19 patients was initially regarded with caution due to their immunosuppressive function but recent research found that systemic glucocorticoids in patients with severe Covid-19 are associated with lower mortality [20] [21] [22] . Moreover, trials to assess the efficacy of biologic agents such as TNFi therapies to improve outcomes in patients with Covid-19 are ongoing 23 . Initially it was proposed that cytokine inhibition may worsen Covid-19 related outcomes via general immune suppression but more recently it has been suggested that inhibition of a cytokine storm may be beneficial 24 . J o u r n a l P r e -p r o o f 6 Data on Covid-19 in patients with BD are limited 5, 6 . Further progress in understanding the implications of Covid-19 in patients with BD, an immune-mediated inflammatory disease, and the effects of anti-inflammatory, immunosuppressive or immunomodulatory therapies on a long-term basis on Covid-19 related outcomes, is urgently needed to help clinicians caring for patients with this condition. In this context, we aimed to assess the prevalence of Covid-19 in a cohort of patients with BD and investigate whether those patients with a long-term treatment with colchicine, TNFi or oral glucocorticoids are at reduced or increased prevalence of Covid-19 related clinical outcomes. A retrospective study was conducted among a population of patients with BD that were recruited from an online systemic autoimmune disease association of Spain. A total of 2356 patients with BD were registered in this system and were invited to participate. Patients ≥ 18 years of age who had been previously diagnosed with BD by a professional and met the International Study Group for BD diagnosis criteria 25 Continuous variables were presented as mean ± standard deviation and categorical variables as frequencies and percentages. Fisher´s exact tests and Student's t-test were used for data analysis. P values of < 0.05 were considered statistically significant. Table 1 shows the descriptive characteristics and co-morbidities of the study population stratified according to Covid-19 positive and negative patients. In this study cohort involving 244 patients with BD, we identified 36 patients with Covid-19 infection. Thus, the prevalence of Covid-19 was 14.75%. Most patients were females (86.1%), and the population had a mean age of 43.95±11.11 years. The mean time since diagnosis of BD was 9.72±8.69 years. In the overall study population, 66.8%, 37.9% and 24.2% of patients were receiving longterm therapy with colchicine, oral glucocorticoids and TNFi, respectively. Note that 12% of patients were receiving colchicine, oral glucocorticoids and TNFi simultaneously and 4% were not taking any of these. Seventeen percent of patients had hypertension, 12% ischemic heart disease, 9.5% chronic kidney disease, 21.1% stroke, 23.6% diabetes mellitus and 11.5% chronic obstructive pulmonary disease. In the present study, for the first time, we reported that the prevalence of Covid-19 in a cohort of patients with BD was 14.75% and investigate whether those patients with a longterm treatment with colchicine, TNFi or oral glucocorticoids are at reduced or increased prevalence of Covid-19 related clinical outcomes. We found that that the prevalence of ageusia, a Covid-19 related symptom was higher in patients taking 1mg/day of colchicine compared to those taking 0.5mg/day. Regarding the long-term use of TNFi, the prevalence of dyspnoea was significantly higher in patients taking TNFi compared with those without therapy. These findings might not support the potential beneficial effect of colchicine on compared to the general population 6 . Concerning the potential protective role of long-term colchicine therapy against Covid-19 infection, available literature reports contrasting findings 8, 9, 14 . Results from a populationbased prospective cohort in patients chronically exposed to chloroquine/hydroxychloroquine indicated that did not differ in risk of Covid-19 nor hospitalization, compared with controls 10 . A study conducted in a cohort of familial Mediterranean fever (FMF) patients with a long-term treatment by colchicine also concluded that those patients whit this immunity disorder, have no additional risk factor for severe Covid-19 infection compared with the general population 8 . Similarly, a retrospective study based on a large healthcare database indicated that no significant difference in terms of rates of usage of hydroxychloroquine or colchicine between subjects who were found positive for Covid-19 and those who were found negative 9 . Among the same line, our findings might not support the potential beneficial effect of colchicine on recovery for Covid-19 in BD patients. Nonetheless, Kobak infection may be less likely to respond. Also, note that the high prevalence of women reported in our study cohort could be explained by differences in motivation. In fact, a recent systemic review reported that gender differences in social network sites usage were observed to be the product of differences in motivation 31 . Secondly, the small sample, the short period study and the fact that the clinical variables were collected only as present or absent might limit more conclusive results. Therefore, our findings should be considered as preliminary and future prospective, randomised, placebo-controlled studies are warranted to analyze the potential benefit of continuous colchicine, TNF-i and glucocorticoids treatments in COVID- 19 . Furthermore, the methodology of the study, which is based on an online survey might be incomplete since we did not have information regarding the daily doses of TNFi and oral glucocorticoids per patient, and the dose could also influence the results. Likewise, there is no information regarding the use of medications in other classes, which may affect the results of the study. Furthermore, the risk of Covid-19 infection is also influenced by environmental characteristics, which have not been controlled. Despite its limitations, this pilot investigation provides novel information on the characteristics of BD patients with Covid-19 infection. In conclusion, our novel data suggest that the prevalence of Covid-19 among patients with BD seems to be higher than that among the general population in Spain. Continuous TNFi therapy might increase the prevalence of worse clinical outcomes such as dyspnea and oral glucocorticoids and colchicine apparently provided no protection against the Covid-19 related clinical outcomes of patients with BD. This study is an initial approach to know how Covid-19 infection behave in patients with BD and provides novel information. Since this study is based on the online response that implies an inclusion bias, future research is warranted to support these preliminary findings. Immunopathogenesis of Behcet's disease Behçet's disease: An overview of etiopathogenesis Management of patients with Behçet's disease during the COVID-19 pandemic Treatment considerations for Behçet disease in the era of COVID-19: A narrative review Behçet's disease: Clinical case series Characteristics and outcomes of Behçet's syndrome patients with Coronavirus Disease 2019: a case series of 10 patients Update of the EULAR recommendations for the management of Behçet's syndrome Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-Term treatment by colchicine in a French endemic area Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia A potential therapeutic tool against COVID-19. Experience of 5 patients Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe covid-19 infection between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence? Colchicine in COVID-19: an Old Drug, New Use Impact of colchicine on mortality in patients with COVID-19: A meta-analysis Colchicine may not be effective in COVID-19 infection; it may even be harmful? Efficacy and Safety of Corticosteroid Treatment in Patients With COVID-19: A Systematic Review and Meta-Analysis COVID-19 in a patient with longterm use of glucocorticoids: A study of a familial cluster Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed International Study Group for Behçet's Disease. Criteria for diagnosis of Behcet's disease Covid-19 in Immune-Mediated Inflammatory Diseases -Case Series from New York Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes Coronavirus breakthrough: dexamethasone is first drug shown to save lives Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis Predisposing and Motivational Factors Related to Social Network Sites Use: Systematic Review The authors thank the participating BD patients. The authors declare no conflict of interest. -Do you have a long-term use oftTumor necrosis factor inhibitors (Anti-TNF drugs) (more than thirty days)? -